Herbalife Achieves Third Quarter Net Sales Growth of 6.0%; Strong Profitability and Robust Operating Cash Flow; Fifth Consecutive Quarter of Expansion

HERBALIFE LTD. (HLF) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 CONFIDENTIAL & PRIVILEGED Herbalife Achieves Third Quarter Net Sales Growth of 6.0%; Strong Profitability and Robust Operating Cash Flow; Fifth Consecutive Quarter of Expansion LOS ANGELES, November 2, 2026 – Herbalife Ltd. (NYSE: HLF) today reported financial result

Event · Earnings
Also in this documentBuyback · $250MGuidance · raise

Facts are quoted from the filing text and checked against it.

Original reporting
Published Nov 2, 2026, 9:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 9:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$HLF
Bullish
high confidence
Mentioned
$HLF
Relevance
8/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$HLFBullishHigh
01

Why it matters

The earnings beat and raised guidance are likely to drive short‑term buying interest, especially in after‑hours trading.

02

Market read

Herbalife's strong quarterly performance and upgraded outlook provide a clear catalyst for the stock.

03

What to watch

FX headwinds and cost pressures in self‑manufacturing could temper profit growth.

Relevance 8/10Novelty 8/10Timing: after-hours
AlphAI · Earnings readHLF · Third Quarter 2026 · ended September 30, 2026

Herbalife Achieves Third Quarter Net Sales Growth of 6.0%; Strong Profitability and Robust Operating Cash Flow; Fifth Consecutive Quarter of Expansion

✓Solid quarter

Third-quarter net sales grew 6.0% and adjusted EBITDA margin expanded 70 basis points year-over-year, while operating cash flow was $151.3 million and full-year net sales guidance was increased. China net sales declined 22.0%, EMEA declined 4.9%, and gross margin declined to 77.3% from 77.7%.

Revenue
$1.35B
6.0% y/y
North America, Q3 2026
$268M
1.7% y/y
EPS · non-GAAP
$0.64
$0.14 y/y
Fourth Quarter 2026 and Full-Year 2026 outlook
Fourth Quarter 2026 reported net sales: +0.5% to +4.5% YoY; Fourth Quarter 2026 constant currency net sales: +2.5% to +6.5% YoY; Full-Year 2026 reported net sales: +4.9% to +5.9% YoY; Full-Year 2026 constant currency net sales: +5.3% to +6.3% YoY

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Net sales, three months ended September 30, 2026GAAP$1.35B–6.0%
Net sales, nine months ended September 30, 2026GAAP$3.99B–6.4%
Net sales growth excluding FX, three months ended September 30, 2026non-GAAP7.6%–7.6%
Gross profit, three months ended September 30, 2026GAAP$1.04B––
Gross profit, nine months ended September 30, 2026GAAP$3.10B––
Gross profit margin, third quarter 2026GAAP77.3%––
Selling expenses, three months ended September 30, 2026GAAP$473.5M––
Selling expenses, nine months ended September 30, 2026GAAP$1.40B––
General and administrative expenses, three months ended September 30, 2026GAAP$432.1M––
General and administrative expenses, nine months ended September 30, 2026GAAP$1.30B––
Operating income, three months ended September 30, 2026GAAP$138.5M––
Operating income, nine months ended September 30, 2026GAAP$405.2M––
Interest expense, net, three months ended September 30, 2026GAAP$31.9M––
Interest expense, net, nine months ended September 30, 2026GAAP$116.1M––
Net income attributable to Herbalife, three months ended September 30, 2026GAAP$58.8M––
Net income attributable to Herbalife, nine months ended September 30, 2026GAAP$94.4M––
Net income margin, third quarter 2026GAAP4.4%––
Adjusted net income, three months ended September 30, 2026non-GAAP$68.5M––
Adjusted net income, nine months ended September 30, 2026non-GAAP$190.8M––
Diluted earnings per share attributable to Herbalife, three months ended September 30, 2026GAAP$0.55–$0.13
Diluted earnings per share attributable to Herbalife, nine months ended September 30, 2026GAAP$0.88––
Adjusted diluted earnings per share, three months ended September 30, 2026non-GAAP$0.64–$0.14
Adjusted diluted earnings per share, nine months ended September 30, 2026non-GAAP$1.77––
Adjusted EBITDA, third quarter 2026non-GAAP$182.4M––
Adjusted EBITDA, nine months ended September 30, 2026non-GAAP$524.7M––
Adjusted EBITDA margin, third quarter 2026non-GAAP13.5%–up 70 basis points
Adjusted EBITDA margin, nine months ended September 30, 2026non-GAAP13.1%––
Adjusted EBITDA at constant currency, third quarter 2026non-GAAP$193.4M––
Credit Agreement EBITDA, third quarter 2026non-GAAP$198.9M––
Net cash provided by operating activities, three months ended September 30, 2026GAAP$151.3M––
Net cash provided by operating activities, nine months ended September 30, 2026GAAP$298M–$63.0 million
Capital expenditures, three months ended September 30, 2026GAAP$18.5M––
Capital expenditures, nine months ended September 30, 2026GAAP$40.7M––

Segments

SegmentRevenueq/qy/y
North America, Q3 2026Second consecutive quarter of year-over-year growth.$267.5M–1.7%
Latin America, Q3 2026Net sales growth excluding FX was 5.1%.$250.2M–9.0%
EMEA, Q3 2026Net sales growth excluding FX was (5.2)%.$259M–(4.9)%
Asia Pacific, Q3 2026Net sales growth excluding FX was 26.1%.$517.9M–18.4%
China, Q3 2026Net sales growth excluding FX was (26.4)%.$55.6M–(22.0)%
Worldwide, Q3 2026Growth was primarily driven by increased sales volume and included 160 basis points of FX headwinds.$1.35B–6.0%
North America, YTD 2026Net sales growth excluding FX was (0.3)%.$788.1M–(0.2)%
Latin America, YTD 2026Net sales growth excluding FX was 6.6%.$737.2M–14.0%
EMEA, YTD 2026Net sales growth excluding FX was (5.8)%.$811.6M–(2.6)%
Asia Pacific, YTD 2026Net sales growth excluding FX was 23.4%.$1.48B–17.0%
China, YTD 2026Net sales growth excluding FX was (24.3)%.$173M–(19.9)%
Worldwide, YTD 2026Net sales growth excluding FX was 6.3%.$3.99B–6.4%

Fourth Quarter 2026 and Full-Year 2026 outlook

  • RevenueFourth Quarter 2026 reported net sales: +0.5% to +4.5% YoY; Fourth Quarter 2026 constant currency net sales: +2.5% to +6.5% YoY; Full-Year 2026 reported net sales: +4.9% to +5.9% YoY; Full-Year 2026 constant currency net sales: +5.3% to +6.3% YoY
  • Tax rateAdjusted effective tax rate of approximately 35%
  • NoteFourth Quarter 2026 adjusted EBITDA: $145 million to $165 million
  • NoteFourth Quarter 2026 constant currency adjusted EBITDA: $155 million to $175 million
  • NoteFourth Quarter 2026 CapEx: $13 million to $23 million
  • NoteFull-Year 2026 adjusted EBITDA: $670 million to $690 million
  • NoteFull-Year 2026 constant currency adjusted EBITDA: $700 million to $720 million
  • NoteFull-Year 2026 CapEx: $55 million to $65 million
  • NoteCapitalized and prepaid SaaS implementation costs of $35 million to $45 million
  • NoteDepreciation and amortization, and amortization of SaaS implementation costs, of $135 million to $145 million

Capital returns

  • Board authorized a new share repurchase program of up to $250 million over three years.
  • No shares were repurchased under the program during the third quarter.
  • Share repurchases were $10.2 million for the nine months ended September 30, 2026.

What drove it

  • Third-quarter net sales growth was primarily driven by increased sales volume.
  • Asia Pacific net sales grew 18.4% on a reported basis and 26.1% excluding FX.
  • Latin America net sales grew 9.0% on a reported basis.
  • The April refinancing reduced net interest expense by $19.1 million year-over-year in the third quarter.
  • Adjusted EBITDA included approximately $11.3 million of FX headwinds year-over-year.

Concerns

  • China net sales declined 22.0% year-over-year, or 26.4% excluding FX, in the third quarter.
  • EMEA net sales declined 4.9% year-over-year, or 5.2% excluding FX, in the third quarter.
  • Gross profit margin declined to 77.3% from 77.7%, primarily due to sales mix pressure and cost changes related to self-manufacturing and sourcing.
  • Third-quarter adjusted diluted EPS included a $0.06 year-over-year FX headwind.
  • John DeSimone was appointed interim CEO effective November 1, 2026, while the Board continues its search for the next Chief Executive Officer.

What to watch

  • Fourth-quarter reported net sales guidance of +0.5% to +4.5% YoY and constant currency net sales guidance of +2.5% to +6.5% YoY.
  • Fourth-quarter adjusted EBITDA guidance of $145 million to $165 million and constant currency adjusted EBITDA guidance of $155 million to $175 million.
  • The execution of the up to $250 million share repurchase program, which is expected to begin in the fourth quarter.
  • The progression of China and EMEA net sales declines.
  • Full-year capitalized and prepaid SaaS implementation costs expected to be approximately $35 million to $45 million, which are not included in capital expenditures.

Balance sheet and cash flow

  • Cash and cash equivalents were $409.2 million as of September 30, 2026.
  • Total debt was $2.0 billion as of September 30, 2026.
  • Net debt was $1,542.7 million as of September 30, 2026.
  • Net leverage ratio was 2.0x as of September 30, 2026, compared to 2.2x as of June 30, 2026.
  • Credit Agreement total leverage ratio was 2.6x as of September 30, 2026, compared to 2.8x as of December 31, 2025.
  • Net cash provided by operating activities was $298.0 million for the nine months ended September 30, 2026, compared to $235.0 million in the prior-year period.
  • Purchases of property, plant and equipment were $40.7 million for the nine months ended September 30, 2026.
  • Net cash used in financing activities was $170.7 million for the nine months ended September 30, 2026.

Analysis

Herbalife reported third-quarter net sales of $1,350.2 million, up 6.0% year-over-year, and said growth was primarily driven by increased sales volume. Net sales increased 7.6% on a constant currency basis, with 160 basis points of FX headwinds. This marked the fifth consecutive quarter of year-over-year net sales growth on both a reported and constant currency basis. Asia Pacific was the principal growth contributor, with reported net sales up 18.4%, while Latin America grew 9.0% and North America grew 1.7%.

Regional performance remained uneven. China net sales fell 22.0% on a reported basis and 26.4% excluding FX, while EMEA declined 4.9% reported and 5.2% excluding FX. North America posted its second consecutive quarter of year-over-year growth, but its year-to-date net sales remained down 0.2%. These regional declines remain important offsets to the acceleration in Asia Pacific and Latin America.

Profitability improved below gross profit despite gross margin declining to 77.3% from 77.7%. The company attributed the gross-margin decline primarily to sales mix pressure and cost changes related to self-manufacturing and sourcing, partially offset by pricing benefits. Adjusted EBITDA rose to $182.4 million and adjusted EBITDA margin reached 13.5%, up 70 basis points year-over-year. Net income attributable to Herbalife was $58.8 million, adjusted net income was $68.5 million, diluted EPS was $0.55, and adjusted diluted EPS was $0.64. The April refinancing reduced third-quarter net interest expense by $19.1 million year-over-year.

Cash generation and leverage improved. Net cash provided by operating activities was $151.3 million in the quarter and $298.0 million year to date, up $63.0 million from the prior-year nine-month period. Cash and cash equivalents were $409.2 million, total debt was $2.0 billion, and the net leverage ratio was 2.0x as of September 30, 2026, compared with 2.2x as of June 30, 2026. The Board authorized a new share repurchase program of up to $250 million over three years, with execution expected to begin in the fourth quarter.

The company guided fourth-quarter reported net sales growth of +0.5% to +4.5% year-over-year and adjusted EBITDA of $145 million to $165 million. Full-year reported net sales guidance was revised to +4.9% to +5.9% year-over-year, while full-year reported adjusted EBITDA guidance was maintained at $670 million to $690 million. Management also increased full-year constant currency adjusted EBITDA guidance to $700 million to $720 million. The guide places attention on sustaining growth outside China and EMEA, protecting margins amid sales mix and sourcing costs, and converting operating momentum into cash while beginning shareholder returns.

Management, verbatim

Third quarter net sales and adjusted EBITDA both exceeded guidance, and adjusted EBITDA margin expanded 70 basis points year-over-year.

Scott Schaefer, CFO

Our April refinancing reduced net interest expense by $19.1 million year-over-year in the third quarter, strengthening our earnings and cash generation.

Scott Schaefer, CFO

We delivered a fifth consecutive quarter of year-over-year net sales growth, and we continue to expect net sales growth for the remainder of the year.

John DeSimone, Interim CEO

Not in the filing

stated, not guessed
  • Free cash flow was not reported.
  • Third-quarter free cash flow and prior-year comparison were not reported.
  • Third-quarter operating income margin was not reported.
  • Quarterly cash flow from financing activities was not reported.
  • Fourth-quarter gross margin guidance was not reported.
  • Fourth-quarter operating expense guidance was not reported.
  • Fourth-quarter tax rate guidance was not reported.
  • Full-year GAAP net income guidance and GAAP EPS guidance were not reported.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

Herbalife filed an 8‑K with Q3 results and updated guidance, including a new $250M share repurchase program.

Company-level read

Ticker impact

$HLFBullishHigh confidence
Context

Herbalife reported Q3 2026 net sales up 6% YoY and raised full-year net sales guidance.

Expected impact

likely upward pressure as investors price in higher sales outlook

Evidence & confidence

Strong top-line growth, margin expansion, and a $250M share repurchase program support a bullish reaction.

Market effects

Consumer staples may see modest uplift as Herbalife's growth signals demand for nutrition products.

North America and Asia Pacific markets could benefit from Herbalife's regional sales gains.

Limited to Herbalife and its peers; no broad market shift expected.

Counterpoint

Higher guidance may already be priced in; focus on rising debt levels and modest margin pressure.

Key entities

  • Herbalife Ltd.

    Nutrition and weight‑management company reporting Q3 2026 results.

  • Scott Schaefer

    New CFO who highlighted the earnings beat and guidance raise.

Every HLF earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$HLFMedAI 8/10

Herbalife Ltd (HLF) (Q3 2026) Earnings Call Highlights: Fifth Straight Quarter

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, beating guidance. Growth was driven by India and nutrition clubs, while EMEA and China saw declines. The company raised full-year sales guidance but expects gradual margin expansion. Interim CEO John DeSimone discussed product repositioning and new technology platforms. Operating cash flow rose 27% YoY, and net leverage improved to 2.0x.

$HLFHighAI 8/10

Why Herbalife Stock Is Up Today

Herbalife (HLF) shares rose 8% after Q3 results showed 6% revenue growth to $1.35B, with Asia Pacific up 18%. Adjusted net income increased 33% to $68.5M. The company raised full-year sales guidance and announced a $250M stock buyback program. According to interim CEO John DeSimone, growth is driven by 3M+ independent distributors.

$HLFMedAI 8/10

Herbalife Reports Q3 2026 Financial Results

Herbalife Ltd. reported Q3 2026 net sales of $1.35B, up 6% YoY, with regional growth varying. Adjusted EBITDA was $182.4M, EPS $0.55. Gross margin slightly declined to 77.3%. The company cited refinancing benefits and debt reduction. Management expects continued net sales growth.

$HLFHighAI 8/10

Herbalife (HLF) Q3 2026 Earnings Call Transcript

Herbalife (HLF) reported Q3 2026 net sales of $1.4B, up 6% YoY, and adjusted EBITDA of $182M, exceeding guidance. Interim CEO John DeSimone highlighted growth opportunities, including strengthening Nutrition Clubs and expanding the Bioniq brand. The company aims to enhance distributor support and technology capabilities.

$HLFMedAI 8/10

What Herbalife (HLF) Said on Its Q3 Earnings Call

Herbalife (HLF) reported Q3 sales growth of 5.1% in constant currency and 9% reported, with North America up 1.7%. FX reduced net sales by $21M. The company outlined priorities: nutrition clubs, tech platforms, and Bioniq brand growth. It expects Q4 sales growth of 0.5% to 4.5% and raised full-year sales guidance to 4.9% to 5.9%. Operating cash flow rose 27% YoY to $298M.